Author Archives: Jennifer Boggs

Utopia, dystopia: Separating truth from fiction in bioethics discussions

Let’s face it: Imagining the means of humanity’s ultimate destruction makes for great entertainment. There are no shortages of novels, movies and television shows featuring threats of global annihilation – zombie viruses, meteors hurtling through space, nuclear warfare – or…

Share

Talk to your doctor: How even annoying DTC ads can contribute to patient communication

A few years ago I went to the nearby immediate care with a minor but irritating cough that wouldn’t go away. Three visits later – after two utterly ineffectual rounds of antibiotics and a prescription for a cough medicine that…

Share

Balancing innovation and access: The policy conundrum

RIO DE JANEIRO – I was in college when I first read Ayn Rand’s Atlas Shrugged. Safe within the privileged and idealistic bubble of academia, I found myself agreeing with Rand at every turn, filled with the pro-capitalist and individualist…

Share

Mystic moldy pizza: Food for thought from Allicense 2014

SAN FRANCISCO – When talking trends in biopharma there’s no shortage of metaphors – Tuesday’s health care debate, for example, went for the timely baseball terms, referencing singles and home runs – or oft-overused industry buzzwords, of which the recent…

Share

Rock to the left, hard place to the right: One dilemma of compassionate use

Before its unfortunate drop in quality in its last few seasons, the medical drama House was one of my favorite shows, with its title character, a cranky, possibly drug-addicted doctor solving diagnostic riddles and saving lives with Sherlockian brilliance, and quite…

Share

Drug pricing: Are we paying for efficacy or innovation?

What if we paid professional athletes only when they won? What if spectators got their tickets refunded whenever the home team lost? That might make that $1,300 Super Bowl ticket a little easier to purchase. And, hey, perhaps that might…

Share

‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’

We at BioWorld actually contemplated putting out a zany blog about biotech to commemorate April Fools’ Day – i.e. biotech firm develops drug for childhood cooties, or something equally ridiculous – but, in the end, we decided to pass. And…

Share

Big Wins, a Cliff, a Race and a Red Face: A 2012 Recap

Now that 2012 is drawing to a close, it’s once again time to take a look back at a year that saw some big hits and misses for the biotech industry – and there were plenty of both. The hits…

Share

#BIO2012: Tips for a Wicked Good Meeting

Heading to Boston next week for the 2012 Biotechnology Industry Organization International convention? So are we. In fact, BioWorld has attended and exhibited at the annual BIO meeting for 18 years, so we know a thing or two about navigating…

Share

Profit vs. Value: When Activist Shareholders Attack

Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…

Share